ArticleInfection and drug resistance2023
Chromosome-Mediated Colistin Resistance in Clinical Isolates of
Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 9 citations in OpenAlex.
- Review
- Molecular analysis of polymyxin B resistance in clinical carbapenem-resistant Klebsiella pneumoniae isolates from a large tertiary care teaching hospital in Southwest China.BMC microbiology · 2026Article
- Unraveling Cefiderocol Resistance in NDM- and OXA-48-like Co-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Chromosomal Mechanisms of Colistin Resistance in Clinical Isolates of Carbapenem-ResistantInfectious disease reports · 2026Article
- Molecular evaluation of colistin resistance inIranian journal of microbiology · 2026Article
- Prevalence and Molecular Characterization of Carbapenemase and Hypervirulence Genes inInternational journal of microbiology · 2026Article
- Resistance to colistin and fosfomycin in extended-spectrum beta-lactamase-producing Escherichia coli.Revista peruana de medicina experimental y salud publica · 2025Article
- Regional Genomic and Phylogenomic Insights into Multidrug and Colistin-Resistant Klebsiella pneumoniae Strains from Tanzania, Kenya, Uganda, and Ethiopia.Current microbiology · 2025Article
- Unraveling the genome-wide repertoire of the novel chromosomally encodedFrontiers in microbiology · 2025Article
- A nosocomial outbreak of colistin and carbapenem-resistant hypervirulent Klebsiella pneumoniae in a large teaching hospital.Scientific reports · 2024Article
- Colistin Resistance Mediated byInfection and drug resistance · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Colistin resistance mechanisms involving mutations in chromosomal genes associated with LPS modification are not completely understood. Mutations in genes coding for the MgrB regulator frequently account for colistin resistance in Methods: Isolates were obtained in a 3-year period in a university hospital in Santiago, Chile. Susceptibility to colistin, aminoglycosides, cephalosporins, carbapenems and ciprofloxacin was determined through broth microdilution. Whole genome sequencing was performed for all isolates and chromosomal gene sequences were compared with sequences of colistin-susceptible isolates of the same sequence types. Results: None of the isolates carried Conclusion: Colistin resistance mechanisms depend on genetic background, and are due to chromosomal mutations, which implies a lower risk of transmission than plasmid-mediated genes. Colistin resistance is not associated with multidrug-resistance, nor to high-risk sequence types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.